Sign in
WithdrawnNo phase

Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study)

Key facts

Who runs it
AHEPA University Hospital
Where
Greece2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Started
1 Aug 2020
Ended
Dec 2023
Type of study
Observational
Treatments tested
  • Low molecular weight heparin
Record updated
30 July 2024
Why it stopped
Not enough participants

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Subjects diagnosed with cancer other than basal-cell or squamous-cell skin cancer which was objectively confirmed and are programmed for antineoplastic treatment
  • Subjects between 18 to 75 years of age at inclusion
  • Subjects must weigh at least 40 kg at inclusion
  • Subjects receiving direct oral anticoagulant treatment (rivaroxaban, dabigatran, apixaban, edoxaban) for prevention of stroke and systemic embolism in non-valvular atrial fibrillation

Who cannot take part

  • Patients that have active or serious bleeding within the previous two weeks
  • Recent brain surgery within 6 months
  • Vascular surgery within 6 months
  • Patients that have conditions associated with high bleeding risk (active peptic ulcer, recent neurosurgery
  • Patients with platelet count below 50000 per cubic millimeter
  • Patients with calculated creatinine clearance < 30 ml/min using the Cockcroft-Gault formula
  • Patients who have contraindications to heparin (heparin-induced thrombocytopenia)
  • Women who are pregnant
  • Life expectancy less than 6 months
  • Anticoagulation contraindications

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The primary objective is to assess the safety and efficacy of switching from direct oral anticoagulants to low molecular weight heparin in cancer patients during antineoplastic therapy

The group in the trial

  • Cancer patients with atrial fibrillation

    All patients will be assigned to receive subcutaneous LMWH in therapeutic doses More specifically the regimens will be as follows: Tinzaparin 175 units/Kg once daily; Enoxaparin 1unit/kg twice daily; Fondaparinux \<50 kg, 5 mg SC once daily, 50-100 kg, 7.5 mg SC once daily, \>100 kg, 10 mg SC once daily; Bemiparin 115 IU/kg once daily; \<50kg, 5000IU, 50-70kg, 7.500 IU, \>70kg, 10000IU Nadroparin: Patients weighing 40 to 100 kg: SC, 171 anti-factor Xa IU per kg of body weight once a day; patients weighing over 100 kg will not receive nadroparin because a treatment dosage has not been established; Dalteparin: 200 units IU/kg SC daily for 30 days, then 150 units IU/Kg SC daily Dose adjustments will occur only in case of renal insufficiency according to the medicine's SPC The treatment with the LMWH will last at least during the period of active antineoplastic therapy of cancer patients

    Treatment: Low molecular weight heparin

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety and Efficacy of Switching From Direct Oral Anticoagulants to Low Molecular Weight Heparin in Cancer Patients With Atrial Fibrillation During Antineoplastic Therapy
Record updated
30 July 2024